| 徐晓坤,曾庆曙,李 婉,马圣宇,杨 云.PCD方案与VAD方案治疗多发性骨髓瘤的疗效及对血清VEGF、β2-MG水平的影响[J].,2021,(6):1112-1115 |
| PCD方案与VAD方案治疗多发性骨髓瘤的疗效及对血清VEGF、β2-MG水平的影响 |
| Effect of PCD Chemotherapy and VAD Chemotherapy on Serum VEGF and β 2-MG Levels in Patients with Multiple Myeloma |
| 投稿时间：2020-09-04 修订日期：2020-09-28 |
| DOI：10.13241/j.cnki.pmb.2021.06.025 |
| 中文关键词: VAD方案 PCD方案 多发性骨髓瘤 疗效 β2 -微球蛋白 血管内皮生长因子 |
| 英文关键词: VAD Regimen PCD Regimen Multiple Myeloma Efficacy β2-microglobulin Vascular Endothelial Growth Factor |
| 基金项目:国家自然科学基金项目（KJ2017A832） |
|
| 摘要点击次数: 860 |
| 全文下载次数: 655 |
| 中文摘要: |
| 摘要 目的：研究表阿霉素+长春新碱+地塞米松（VAD方案）和环磷酰胺+硼替佐米+地塞米松（PCD方案）对多发性骨髓瘤的疗效及对血清β2 -微球蛋白（β2-microglobulin, β2-MG）、血管内皮生长因子（Vascular endothelial growth factor, VEGF）水平的影响。方法：选择2017年1月～2020年1月于我院诊治的40例多发性骨髓瘤患者，将其随机分为两组。对照组采用VAD方案治疗，观察组采用PCD方案治疗。比较两组的近期疗效、血清VEGF和β2-MG水平、毒性反应发生情况。结果：观察组的有效率50.00 %明显高于对照组20.00 %(P<0.05)；治疗后，两组的血清VEGF和β2-MG水平明显降低，且观察组低于对照组(P<0.05)；两组腹胀、血细胞缺乏或减少、周围神经毒性的总发生率无明显差异(P<0.05)，且观察组血细胞缺乏或减少发生率5.00 %明显低于对照组(P<0.05)，周围神经毒性发生率30.00 %明显高于对照组(P<0.05)。结论：PCD方案对于多发性骨髓瘤患者的近期疗效明显优于VAD方案，且能明显改善患者的血清VEGF和β2-MG水平，但是必须注意控制剂量，以防止发生周围神经毒性。 |
| 英文摘要: |
| ABSTRACT Objective: To study the efficacy of epirubicin + vincristine + dexamethasone (VAD) and cyclophosphamide + bortezomib + dexamethasone (PCD) in the treatment of multiple myeloma and the effects on the serum levels of β2-MG and VEGF. Methods: Selected 40 cases of patients with multiple myeloma who were treated in our hospital from January 2017 to January 2020, divided into two groups randomly. The control group was treated with VAD regimen, and the observation group was treated with PCD regimen. The short-term efficacy, serum VEGF and β2-MG levels, and toxicity were compared between the two groups. Results: The effective rate of the observation group 50.00 % was significantly higher than that of the control group 20.00 %(P<0.05). After treatment, the serum VEGF and β2-MG levels of the two groups were significantly decreased, and the observation group were significantly lower than those of the control group (P<0.05). There was no significant difference in the total incidence of abdominal distension, blood cell deficiency or reduction and peripheral neurotoxicity between the two groups (P<0.05), and the incidence of blood cell deficiency or reduction in the observation group 5.00 % was significantly lower than that in the control group(P<0.05), and the incidence of peripheral neurotoxicity 30.00 % in the observation group was significantly higher than that in the control group(P<0.05). Conclusion: The short-term efficacy of PCD regimen is better than that of VAD regimen in patients with multiple myeloma, and can significantly improve the serum VEGF and β2-MG levels of patients. However, the dose should be controlled to prevent peripheral neurotoxicity. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
